Mitsubishi Tanabe Pharma makes proprietary prescription pharmaceuticals in a number of therapeutic areas, including cardiovascular disease, diabetes, neuroscience, immunology, and oncology. In its home market, it sells products such as anticoagulant Anplag, anti-allergy medicine Talion, liver drug Urso, and neuroprotective agent Radicut. Its Benesis unit makes therapeutic plasma proteins such as albumin. The company markets and sells its products through in-house sales agents and distributors. Formerly Mitsubishi Pharma, the company merged with fellow Japanese drugmaker Tanabe Seiyaku and subsequently changed its name; Mitsubishi Chemical Holdings owns a majority stake in the new entity.

Experimental and Applied Sciences (EAS) makes and distributes dietary supplements and weight-management products worldwide. The firm's shakes, nutrition bars, protein drinks, and nutritional supplements -- branded as AdvantEdge, Catapult, EAS, Muscle Armor, and Myoplex -- fuel dieters, body builders, and other athletes. EAS also sells training and exercise videos as well as best-selling book, Body for Life (written by one-time owner Bill Phillips). EAS is part of Abbott Nutrition, a division of leading health care products maker Abbott Laboratories.

Champions Biotechnology, Inc. company was founded in 1985 and is based in Baltimore, Maryland. Champions Biotechnology, Inc., a biotechnology company, engages in the development of advanced preclinical platforms and predictive tumor specific data to enhance the value of oncology drugs in the United States. Its preclinical platform is an approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts) in a manner that preserves the biological characteristics of the original human tumor. The company leverages its preclinical platform to evaluate and develop a portfolio of oncology drug candidates through preclinical trials; and plans to sell, partner or license such drug candidates to pharmaceutical and/or biotechnology companies.Champions Biotechnology provides Personalized Oncology Services to physicians in the field of oncology by establishing and administering expert medical information panels for their patients to analyze medical records and test results; to assist in understanding conventional and experimental options; and to identify and arrange for testing, analysis, and study of the patients cancer tissues. In addition, the company offers personalized Tumorgraft development and drug studies to physicians for evaluating the effects of cancer therapies on their patient's. It offers its platform and tumor specific data to other biotechnology and pharmaceutical companies. The company was formerly known as Champions Sports, Inc. and changed its name to Champions Biotechnology, Inc. in January 2007 as a result of change in its business focus towards biotechnology.

BD Biosciences company, a division of medical equipment firm Becton, Dickinson (BD), provides research supplies to the life sciences market. Its primary Cell Analysis unit offers cell imaging devices, flow cytometers (for cell sorting), and chemical reagents and antibodies (proteins) for cellular analysis. The Discovery Labware unit makes basic lab supplies including pipettes, tubes, and cell culture kits. In addition to scientific researchers and drug developers, BD Biosciences counts among its customers blood banks, hospitals, and clinical labs. The company sells its goods around the world through direct and indirect marketing reps and independent distributors.

Optimer Pharmaceuticals was founded in 1998 and is based in San Diego, California. Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide. The company develops products that treat gastrointestinal infections and related diseases. Its two late-stage anti-infective product candidates include Fidaxomicin, the lead product candidate and an antibiotic that is in second Phase III registration trial for the treatment of clostridium difficile-infections; and Prulifloxacin, a prodrug in the fluoroquinolone class of antibiotics, which completed second Phase III trials for the treatment of infectious diarrhea in travelers. It also develops OP-1068/CEM-101, an antibiotic for the treatment of upper and lower respiratory tract infections; OPT-88, a disease-modifying intra-articular, or within the cavity of a joint, therapy for osteoarthritis; OPT-822, a carbohydrate-based cancer immunotherapy for the treatment of metastatic breast cancer; and an OPopS drug discovery platform. The company has a collaborative research and development, and license agreement with Cempra Pharmaceuticals, Inc. to discover, develop, and commercialize drugs based on macrolide and ketolide compounds.

Curis, Inc. company was founded in 2000 and is based in Cambridge, Massachusetts. Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, in collaboration with Genentech, is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and in advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and epidermal growth factor receptor 2 (Her2). In addition, Curis has a development candidate, CUDC-305, a Heat Shock Protein 90 (Hsp90) inhibitor.

Coating Place, Inc. is a privately owned contract manufacturing organization specializing in pharmaceutical grade Wurster fluid bed coating services for encapsulation/microencapsulation of solid particulate materials such as powders, granules, crystals, and capsules. Services offered include pharmaceutical GMP contract manufacturing, process validation, technology transfer, scale-up, formulation development, feasibility studies, and GMP analytical laboratory support.Applications include controlled oral delivery such as enteric, delayed, or sustained release, taste, odor masking, and moisture or oxygen barrier application for Rx prescription, OTC, and controlled substance markets. Facilities are permitted for solvent applications; thus, allowing solvent, aqueous, and hot melt Wurster processing.

Metabasis Therapeutics, Inc. company was founded in 1997 and is based in La Jolla, California. Metabasis Therapeutics, Inc. (Metabasis) is a biopharmaceutical company focused on the discovery development of drugs. The Company’s product pipeline includes product candidates and advanced discovery programs for the treatment of metabolic diseases such as diabetes and hyperlipidemia, which it refer to as its core assets, as well as product candidates and advanced discovery programs for the treatment of liver diseases such as hepatitis and primary liver cancer, which it refer to as its non-core assets. All of its product candidates were developed internally using its HepDirect technology. The Company’s pipeline of clinical-stage product candidates also consists of its core asset, MB07803, a product candidate for the treatment of type 2 diabetes, and its non-core assets, pradefovir and MB07133, developed for the treatment of hepatitis B and primary liver cancer, respectively.

CK Life Sciences champions good health and sustainable growth in its business and elsewhere. The company specializes in the development of yeast-based fertilizers and nutritional supplements. Its VitaGain line of nutritional products are sold in Asia. In the US its Vitaquest International (doing business as Garden State Nutritionals) subsidiary is a contract manufacturer of nutritional supplements. Its Australian subsidiaries manufacture commercial and retail fertilizers and gardening products. Other subsidiaries conduct biotech research and development. CK Life Sciences is part of Cheung Kong.

Futura Medical plc company, which develops pharmaceutical and other medical products for sexual dysfunctions in both men and women, uses the DermaSys technology in its MED2002 non-prescription topical gel being developed with GlaxoSmithKline as an erectile dysfunction product. Futura is exploring other applications for DermaSys as MED2002 continues clinical trials. Other products include CSD500, a device to reduce condom slippage, and FLD 500, the company's Female Lubrication Device that is globally marketed and distributed by SSL International.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.